西格列汀对需要大剂量胰岛素治疗的老年T2DM患者胰岛素抵抗及血糖波动的影响

目的 观察西格列汀对需要大剂量胰岛素治疗的老年2型糖尿病(T2DM)患者胰岛素抵抗及血糖波动的影响.方法 100例需要大剂量胰岛素治疗的老年T2DM患者分成两组:西格列汀组应用磷酸西格列汀片,每次100 mg,1次/天,口服;吡格列酮组应用盐酸吡格列酮片,每次15 mg,1次/天,口服.两组均同时应用胰岛素,疗程均为12周.比较两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、24 h葡萄糖曲线下面积(AUC)、血糖变异系数(CV)、空腹C肽(FCP)、餐后2hC肽(2hPCP)、空腹胰高血糖素(PGG)、餐后2h胰高血糖素(2hPGG)、胆固醇(TC)、三酰甘油(TG)、收缩压(SBP)、舒张压(DBP)、日胰岛素用量(DID)、体质量指数(BMI)、血清CA19-9及血尿酸(BUA)、低血糖发生的频次及药物的不良反应.结果 治疗12周后,西格列汀组患者的FPG、2hPG、HbA1c、AUC、CV、PGG、2hPGG、TC、TG、SBP、DBP、DID及BMI均较治疗前明显降低(P＜0.05或P＜0.01);吡格列酮组患者的FPG、2hPG、HbA1c、AUC、CV及BUA均较治疗前明显降低(P＜0.05或P＜0.01);西格列汀组患者治疗后的2hPG、HbA1c、AUC、CV、PGG、2hPGG、TC、TG、SBP、DBP、DID及BMI均低于吡格列酮组(均P＜0.05),西格列汀组患者治疗后的FCP及2hPCP均高于吡格列酮组(P＜0.01);西格列汀组的低血糖发生率低于吡格列酮组(P=0.045).西格列汀组的不良反应发生率低于对照组(P=0.043).结论 与吡格列酮相比,对需要大剂量胰岛素治疗的老年T2DM患者应用西格列汀可以减轻胰岛素抵抗,减少胰岛素剂量,降低低血糖发生率.

Effect of sitagliptin on insulin resistance and glucose variability in elderly patients with type 2 diabetes mellitus requiring high-dose insulin therapy

Objective To study the effect of sitagliptin on insulin resistance and glucose variability in elderly patients with type 2 diabetes mellitus(T2DM) requiring high-dose insulin therapy.Methods A total of 100 elderly patients with T2DM failing to reach the standard application of large-dose insulin(＞60 U/d) treatment for three months or more glycosylated hemoglobin (HbA1c) ＞8.0％] was randomly divided into sitagliptin group and pioglitazone group.Patients in sitagliptin group(50 cases) were treated with sitagliptin for oral use,100 mg each time,once a day,and patients in pioglitazone group(50 cases) were treated with pioglitazone for oral use,15 mg each time,once a day.The insulin dose was adjusted according to the blood glucose level in the two groups.Two groups were treated for 12 weeks.The indicators in both groups were compared,including fasting blood glucose (FBG),2 hours postprandial glucose (2hPG),glycosylated hemoglobin (HbA1c),24 hours glucose area under the curve (AUC),blood glucose coefficient of variation (CV),fasting C-peptide (FCP),2 hours postprandial C-peptide (2hPCP),fasting glucagon (FGG),2 hours postprandial glucagon(2 hFGG),cholesterol (TC),triglyceride (TG),systolic blood pressure (SBP),diastolic blood pressure(DBP),blood uric acid(BUA),daily insulin dosage(DID),body mass index(BMI),incidence of hypoglycemia and drug adverse reactions.Results After 12 weeks of treatment,the levels of FPG,2hPG,HbA1c,AUC,CV,FGG,2hFGG,TC,TG,SBP,DBP,DID and BMI in the sitagliptin group were significantly decreased than those before treatment(P＜0.05 or P＜0.01);The levels of FPG,2hPG,H bA1c,AUC,CV and BUA in the pioglitazone group were significantly decreased than those before treatment (P＜ 0.0 5 or P＜ 0.01);Compared with the pioglitazone group,the levels of 2 hPG,HbA1c,AUC,CV,FGG,2 hFGG,TC,TG,SBP,DBP,DID and BMI were significantly decreased in the sitagliptin group(all P＜0.05),and the levels of FCP and 2hPCP in the sitagliptin group were higher than those in the pioglitazone group(all P＜0.01).The incidence of hypoglycemia in the sitagliptin group was lower than that in the pioglitazone group(x2 =4.039,P =0.045).The incidence of adverse reactions in the sitagliptin group was lower than that in the pioglitazone grouP(x2 =3.979,P=0.043).Conclusion Sitagliptin combined with insulin is better than insulin combined with pioglitazone in elderly patients with T2DM requiring the application of high-dose insulin therapy,and the combining treatment could decrease insulin resistance,insulin dosage and the incidence of hypoglycemia.